Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

Withdrawn before enrolling · Not applicable

Conditions studied: Genitourinary Syndrome of Menopause (GSM)

In brief

This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.

Key facts

Study ID

NCT07038070

Run by

NYU Langone Health

People needed

0

Starts

2025-07-01

Expected to finish

2026-05-01

Last updated by the study team

2026-05-04

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal (last menstrual period at least 12 months ago).
• Aged 45 years or older and have symptoms of Genitourinary Syndrome of Menopause (GSM).
• Have never tried vaginal estrogen therapy, or have tried vaginal estrogen therapy, but have not used vaginal estrogen and/or hyaluronic acid products for management of GSM symptoms within the last 3 months.
• Capable of signing informed consent.
• Capable and willing to follow all study-relation visits.

You may not qualify if…

• Subjects currently diagnosed with or undergoing treatment for hormone-sensitive disease (e.g. breast cancer)
• Subjects currently using systemic hormone replacement therapy
• Subjects currently using estrogen hormonal therapies or hormone modulators (aromatase inhibitors or selective estrogen receptor modulators)

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.